Boston Scientific (BSX) Accumulated Expenses (2009 - 2026)

Boston Scientific (BSX) has 18 years of Accumulated Expenses data on file, last reported at $2.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 6.8% year-over-year to $2.5 billion; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (up 6.8% YoY), and the FY2025 full-year result was $3.2 billion, up 15.43% from the prior year.
• Accumulated Expenses slipped to $2.5 billion in Q1 2026, from $3.2 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.2 billion in Q4 2025 to a low of $1.9 billion in Q1 2023.
• A 5-year average of $2.4 billion and a median of $2.3 billion in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses declined 18.36% in 2022 and gained 22.5% in 2023, its largest moves.
• Tracing BSX's Accumulated Expenses over 5 years: stood at $2.2 billion in 2022, then advanced by 22.5% to $2.6 billion in 2023, then advanced by 4.8% to $2.8 billion in 2024, then advanced by 15.43% to $3.2 billion in 2025, then decreased by 21.46% to $2.5 billion in 2026.
• Business Quant data shows BSX's Accumulated Expenses at $2.5 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.0 billion in Q3 2025.